Tesamorelin
Body composition is about more than a number on the scale. Whether your priority is a changing waistline, strength or metabolic health, a personal conversation can help you understand tesamorelin research and the options relevant to you.
Start with a free consultation.
No deposit. Our Gilbert team will contact you within one business day.
Explore Tesamorelin
Explore tesamorelin and visceral-fat research, then discuss your waist, strength and metabolic-health priorities with LifeSpann.
Tesamorelin is a growth-hormone-releasing hormone analog studied for its effects on visceral fat. The FDA-approved EGRIFTA product has a specific indication for excess abdominal fat in adults with HIV-associated lipodystrophy, rather than general weight-loss management.
Your goals may involve fat distribution, strength, physical function or the way your body feels. We can help you separate those priorities and discuss the evidence, evaluation and available care options that fit your circumstances.
What to expect from your free consultation
A conversation about your goals, the research and care options. Bring your questions; you can explore the possibilities without choosing a peptide or combination in advance.
Discuss what you want to change and how it affects your day.
Understand the science, relevant evidence and currently available approaches.
Discuss suitability and whether a further evaluation or care option fits your goals.
Free consultation, no deposit. Request a conversation below; our front desk contacts you within one business day to schedule.
Request your free consultationThe science behind Tesamorelin
Tesamorelin stimulates pituitary growth hormone release and downstream IGF-1 activity. Acting through that signaling system does not eliminate risks from increased growth hormone activity.
From pituitary signal to IGF-1
Read the illustration
- GHRH receptor
Tesamorelin activates this receptor in the pituitary.
- Growth hormone
Pituitary cells release growth hormone in response.
- IGF-1
Downstream signaling includes increased IGF-1 activity.
The illustration summarizes the GH/IGF-1 axis. Clinical findings depend on the product, indication and population studied. Colors and structures are simplified for illustration.
Read the tesamorelin prescribing informationWhat the evidence shows
Product- and indication-specific clinical evidence
The EGRIFTA WR label supports its use for excess abdominal fat in adults with HIV and lipodystrophy. It specifically excludes general weight-loss management; long-term cardiovascular safety has not been established.
Where the Research Is Still Developing
- Evidence for an approved product cannot simply be transferred to a compounded formulation.
- A change in visceral fat is not proof of longer life, improved cognition or benefit for every person with abdominal weight.
Safety & Your Care Options
Your clinician reviews suitability and current treatment availability with you. Some topics here involve investigational compounds; a research guide is not an offer to prescribe every product described.
- The label contraindicates use in pregnancy, active malignancy and certain pituitary-axis disorders.
- Elevated IGF-1, glucose intolerance, fluid retention and hypersensitivity require clinician attention.
Bring your goals to the conversation
Tell us what you want to achieve and what you have already tried. We’ll help you put the research in context, compare available approaches and plan your next step. You do not need to arrive with a peptide selected.
- Is my concern weight, waist size, metabolic risk or loss of strength?
- What evidence applies to my health history rather than a different study population?
- Which alternatives and monitoring requirements should we discuss?
Considering Tesamorelin? Start here.
Explore your options and what to expect from a conversation with LifeSpann.
Can I discuss abdominal fat or body-composition goals with LifeSpann?
Yes. Bring the changes you have noticed, your current plan and the outcome that matters to you. We can discuss tesamorelin research in context and whether a broader metabolic or weight-management evaluation would be a useful next step.
How does tesamorelin differ from general weight-loss treatment?
The FDA-approved EGRIFTA product has a specific indication for excess abdominal fat in adults with HIV-associated lipodystrophy. That evidence does not establish tesamorelin as general weight-loss treatment. Your conversation can help you compare options suited to your own health history and goals.
Can we review tesamorelin alongside my current weight-management plan?
Yes. Bring your medicines, available labs and recent progress. We can discuss the purpose of each proposed treatment and the evidence for combining approaches. Blood sugar, IGF-1 and fluid-related effects belong in that review; a plateau alone does not determine the next treatment.
What does the free consultation include?
Start with a conversation about your goals, the research and available care options. The peptide education consultation is free, with no deposit or purchase required. You do not need to choose a peptide first. Any recommended testing or treatment and its cost are discussed separately before you decide.
How do I get started with LifeSpann?
Use the consultation request form with your name, phone and email. Our front desk will contact you within one business day to answer scheduling questions and arrange your visit. You can save your health details for the clinical conversation. Sending the form requests a callback; your appointment is confirmed when we schedule it with you.
Sources and further reading
- EGRIFTA WR prescribing information
U.S. Food and Drug Administration · 2025 - Understanding the risks of compounded drugs
U.S. Food and Drug Administration · Current guidance
Read the original studies and guidance behind this page. Findings apply to the products and populations studied. Meet our team.
Start with your goals. The consultation is free.
Free consultation · No deposit
Bring your goals and questions. We’ll explore the research, your health priorities and the available care options together. You do not need to choose a peptide first.
Our front desk will contact you within one business day to answer questions and schedule your consultation.
Prefer to call? (480) 351-7151